nodes	percent_of_prediction	percent_of_DWPC	metapath
Palonosetron—CYP3A4—bone cancer	0.87	1	CbGaD
Palonosetron—Praziquantel—CYP3A4—bone cancer	0.00573	1	CrCbGaD
Palonosetron—Hiccups—Epirubicin—bone cancer	0.000682	0.00547	CcSEcCtD
Palonosetron—Bradycardia—Cisplatin—bone cancer	0.000679	0.00545	CcSEcCtD
Palonosetron—Injection site reaction—Epirubicin—bone cancer	0.000678	0.00544	CcSEcCtD
Palonosetron—Dyskinesia—Doxorubicin—bone cancer	0.000671	0.00539	CcSEcCtD
Palonosetron—Hyperkalaemia—Epirubicin—bone cancer	0.00067	0.00538	CcSEcCtD
Palonosetron—Salivary hypersecretion—Epirubicin—bone cancer	0.000662	0.00532	CcSEcCtD
Palonosetron—Influenza like illness—Epirubicin—bone cancer	0.000662	0.00532	CcSEcCtD
Palonosetron—Urinary tract disorder—Cisplatin—bone cancer	0.000658	0.00529	CcSEcCtD
Palonosetron—Connective tissue disorder—Cisplatin—bone cancer	0.000655	0.00526	CcSEcCtD
Palonosetron—Urethral disorder—Cisplatin—bone cancer	0.000654	0.00525	CcSEcCtD
Palonosetron—Fluid retention—Epirubicin—bone cancer	0.000647	0.0052	CcSEcCtD
Palonosetron—Hiccups—Doxorubicin—bone cancer	0.000631	0.00506	CcSEcCtD
Palonosetron—Injection site reaction—Doxorubicin—bone cancer	0.000627	0.00503	CcSEcCtD
Palonosetron—Eye disorder—Cisplatin—bone cancer	0.000623	0.005	CcSEcCtD
Palonosetron—Tinnitus—Cisplatin—bone cancer	0.000622	0.00499	CcSEcCtD
Palonosetron—Hyperkalaemia—Doxorubicin—bone cancer	0.00062	0.00498	CcSEcCtD
Palonosetron—Cardiac disorder—Cisplatin—bone cancer	0.000619	0.00497	CcSEcCtD
Palonosetron—Salivary hypersecretion—Doxorubicin—bone cancer	0.000613	0.00492	CcSEcCtD
Palonosetron—Influenza like illness—Doxorubicin—bone cancer	0.000613	0.00492	CcSEcCtD
Palonosetron—Immune system disorder—Cisplatin—bone cancer	0.000602	0.00483	CcSEcCtD
Palonosetron—Mediastinal disorder—Cisplatin—bone cancer	0.000601	0.00482	CcSEcCtD
Palonosetron—Fluid retention—Doxorubicin—bone cancer	0.000599	0.00481	CcSEcCtD
Palonosetron—Arrhythmia—Cisplatin—bone cancer	0.000596	0.00478	CcSEcCtD
Palonosetron—Alopecia—Cisplatin—bone cancer	0.000589	0.00473	CcSEcCtD
Palonosetron—Erythema—Cisplatin—bone cancer	0.00058	0.00466	CcSEcCtD
Palonosetron—Malnutrition—Cisplatin—bone cancer	0.00058	0.00466	CcSEcCtD
Palonosetron—Flatulence—Cisplatin—bone cancer	0.000572	0.00459	CcSEcCtD
Palonosetron—Anaphylactoid reaction—Methotrexate—bone cancer	0.000546	0.00439	CcSEcCtD
Palonosetron—Anaemia—Cisplatin—bone cancer	0.000536	0.00431	CcSEcCtD
Palonosetron—Hot flush—Epirubicin—bone cancer	0.000529	0.00425	CcSEcCtD
Palonosetron—Menopausal symptoms—Epirubicin—bone cancer	0.000525	0.00421	CcSEcCtD
Palonosetron—Anaphylactoid reaction—Epirubicin—bone cancer	0.000511	0.00411	CcSEcCtD
Palonosetron—Convulsion—Cisplatin—bone cancer	0.000503	0.00404	CcSEcCtD
Palonosetron—Pain in extremity—Epirubicin—bone cancer	0.000495	0.00397	CcSEcCtD
Palonosetron—Myalgia—Cisplatin—bone cancer	0.000494	0.00397	CcSEcCtD
Palonosetron—Anxiety—Cisplatin—bone cancer	0.000492	0.00395	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000491	0.00394	CcSEcCtD
Palonosetron—Hot flush—Doxorubicin—bone cancer	0.00049	0.00393	CcSEcCtD
Palonosetron—Discomfort—Cisplatin—bone cancer	0.000488	0.00392	CcSEcCtD
Palonosetron—Menopausal symptoms—Doxorubicin—bone cancer	0.000485	0.0039	CcSEcCtD
Palonosetron—Anaphylactic shock—Cisplatin—bone cancer	0.000474	0.0038	CcSEcCtD
Palonosetron—Anaphylactoid reaction—Doxorubicin—bone cancer	0.000473	0.0038	CcSEcCtD
Palonosetron—Infection—Cisplatin—bone cancer	0.000471	0.00378	CcSEcCtD
Palonosetron—Nervous system disorder—Cisplatin—bone cancer	0.000465	0.00373	CcSEcCtD
Palonosetron—Tachycardia—Cisplatin—bone cancer	0.000462	0.00371	CcSEcCtD
Palonosetron—Skin disorder—Cisplatin—bone cancer	0.00046	0.00369	CcSEcCtD
Palonosetron—Pain in extremity—Doxorubicin—bone cancer	0.000458	0.00368	CcSEcCtD
Palonosetron—Abdominal pain upper—Epirubicin—bone cancer	0.000452	0.00363	CcSEcCtD
Palonosetron—Anorexia—Cisplatin—bone cancer	0.000452	0.00362	CcSEcCtD
Palonosetron—Hypokalaemia—Epirubicin—bone cancer	0.00045	0.00362	CcSEcCtD
Palonosetron—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.000446	0.00358	CcSEcCtD
Palonosetron—Hypotension—Cisplatin—bone cancer	0.000443	0.00355	CcSEcCtD
Palonosetron—Gastritis—Epirubicin—bone cancer	0.000438	0.00352	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000432	0.00346	CcSEcCtD
Palonosetron—Abdominal distension—Epirubicin—bone cancer	0.000431	0.00346	CcSEcCtD
Palonosetron—Paraesthesia—Cisplatin—bone cancer	0.000425	0.00341	CcSEcCtD
Palonosetron—Dyspnoea—Cisplatin—bone cancer	0.000422	0.00339	CcSEcCtD
Palonosetron—Abdominal pain upper—Doxorubicin—bone cancer	0.000418	0.00336	CcSEcCtD
Palonosetron—Hypokalaemia—Doxorubicin—bone cancer	0.000417	0.00335	CcSEcCtD
Palonosetron—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.000412	0.00331	CcSEcCtD
Palonosetron—Decreased appetite—Cisplatin—bone cancer	0.000412	0.00331	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Cisplatin—bone cancer	0.000409	0.00328	CcSEcCtD
Palonosetron—Gastritis—Doxorubicin—bone cancer	0.000405	0.00325	CcSEcCtD
Palonosetron—Pain—Cisplatin—bone cancer	0.000405	0.00325	CcSEcCtD
Palonosetron—Abdominal distension—Doxorubicin—bone cancer	0.000398	0.0032	CcSEcCtD
Palonosetron—Hyperglycaemia—Epirubicin—bone cancer	0.000386	0.0031	CcSEcCtD
Palonosetron—Hepatobiliary disease—Methotrexate—bone cancer	0.000385	0.00309	CcSEcCtD
Palonosetron—Epistaxis—Methotrexate—bone cancer	0.000384	0.00309	CcSEcCtD
Palonosetron—Body temperature increased—Cisplatin—bone cancer	0.000374	0.00301	CcSEcCtD
Palonosetron—Urinary tract disorder—Methotrexate—bone cancer	0.000361	0.0029	CcSEcCtD
Palonosetron—Hepatobiliary disease—Epirubicin—bone cancer	0.000361	0.0029	CcSEcCtD
Palonosetron—Epistaxis—Epirubicin—bone cancer	0.00036	0.00289	CcSEcCtD
Palonosetron—Urethral disorder—Methotrexate—bone cancer	0.000359	0.00288	CcSEcCtD
Palonosetron—Sinusitis—Epirubicin—bone cancer	0.000358	0.00287	CcSEcCtD
Palonosetron—Hyperglycaemia—Doxorubicin—bone cancer	0.000357	0.00287	CcSEcCtD
Palonosetron—Hypersensitivity—Cisplatin—bone cancer	0.000349	0.0028	CcSEcCtD
Palonosetron—Bradycardia—Epirubicin—bone cancer	0.000349	0.0028	CcSEcCtD
Palonosetron—Eye disorder—Methotrexate—bone cancer	0.000342	0.00274	CcSEcCtD
Palonosetron—Tinnitus—Methotrexate—bone cancer	0.000341	0.00274	CcSEcCtD
Palonosetron—Asthenia—Cisplatin—bone cancer	0.00034	0.00273	CcSEcCtD
Palonosetron—Cardiac disorder—Methotrexate—bone cancer	0.00034	0.00273	CcSEcCtD
Palonosetron—Urinary tract disorder—Epirubicin—bone cancer	0.000338	0.00271	CcSEcCtD
Palonosetron—Connective tissue disorder—Epirubicin—bone cancer	0.000336	0.0027	CcSEcCtD
Palonosetron—Urethral disorder—Epirubicin—bone cancer	0.000336	0.00269	CcSEcCtD
Palonosetron—Hepatobiliary disease—Doxorubicin—bone cancer	0.000334	0.00268	CcSEcCtD
Palonosetron—Epistaxis—Doxorubicin—bone cancer	0.000333	0.00267	CcSEcCtD
Palonosetron—Angiopathy—Methotrexate—bone cancer	0.000332	0.00266	CcSEcCtD
Palonosetron—Sinusitis—Doxorubicin—bone cancer	0.000331	0.00266	CcSEcCtD
Palonosetron—Immune system disorder—Methotrexate—bone cancer	0.00033	0.00265	CcSEcCtD
Palonosetron—Mediastinal disorder—Methotrexate—bone cancer	0.00033	0.00265	CcSEcCtD
Palonosetron—Chills—Methotrexate—bone cancer	0.000328	0.00264	CcSEcCtD
Palonosetron—Diarrhoea—Cisplatin—bone cancer	0.000324	0.0026	CcSEcCtD
Palonosetron—Alopecia—Methotrexate—bone cancer	0.000323	0.0026	CcSEcCtD
Palonosetron—Bradycardia—Doxorubicin—bone cancer	0.000323	0.00259	CcSEcCtD
Palonosetron—Mental disorder—Methotrexate—bone cancer	0.000321	0.00257	CcSEcCtD
Palonosetron—Eye disorder—Epirubicin—bone cancer	0.00032	0.00257	CcSEcCtD
Palonosetron—Tinnitus—Epirubicin—bone cancer	0.000319	0.00256	CcSEcCtD
Palonosetron—Erythema—Methotrexate—bone cancer	0.000318	0.00256	CcSEcCtD
Palonosetron—Malnutrition—Methotrexate—bone cancer	0.000318	0.00256	CcSEcCtD
Palonosetron—Cardiac disorder—Epirubicin—bone cancer	0.000318	0.00255	CcSEcCtD
Palonosetron—Urinary tract disorder—Doxorubicin—bone cancer	0.000313	0.00251	CcSEcCtD
Palonosetron—Dysgeusia—Methotrexate—bone cancer	0.000312	0.0025	CcSEcCtD
Palonosetron—Connective tissue disorder—Doxorubicin—bone cancer	0.000311	0.0025	CcSEcCtD
Palonosetron—Angiopathy—Epirubicin—bone cancer	0.000311	0.00249	CcSEcCtD
Palonosetron—Urethral disorder—Doxorubicin—bone cancer	0.000311	0.00249	CcSEcCtD
Palonosetron—Immune system disorder—Epirubicin—bone cancer	0.000309	0.00248	CcSEcCtD
Palonosetron—Mediastinal disorder—Epirubicin—bone cancer	0.000309	0.00248	CcSEcCtD
Palonosetron—Chills—Epirubicin—bone cancer	0.000307	0.00247	CcSEcCtD
Palonosetron—Arrhythmia—Epirubicin—bone cancer	0.000306	0.00246	CcSEcCtD
Palonosetron—Alopecia—Epirubicin—bone cancer	0.000303	0.00243	CcSEcCtD
Palonosetron—Vomiting—Cisplatin—bone cancer	0.000301	0.00242	CcSEcCtD
Palonosetron—Mental disorder—Epirubicin—bone cancer	0.0003	0.00241	CcSEcCtD
Palonosetron—Rash—Cisplatin—bone cancer	0.000299	0.0024	CcSEcCtD
Palonosetron—Dermatitis—Cisplatin—bone cancer	0.000298	0.0024	CcSEcCtD
Palonosetron—Malnutrition—Epirubicin—bone cancer	0.000298	0.00239	CcSEcCtD
Palonosetron—Erythema—Epirubicin—bone cancer	0.000298	0.00239	CcSEcCtD
Palonosetron—Eye disorder—Doxorubicin—bone cancer	0.000296	0.00238	CcSEcCtD
Palonosetron—Tinnitus—Doxorubicin—bone cancer	0.000295	0.00237	CcSEcCtD
Palonosetron—Anaemia—Methotrexate—bone cancer	0.000294	0.00236	CcSEcCtD
Palonosetron—Cardiac disorder—Doxorubicin—bone cancer	0.000294	0.00236	CcSEcCtD
Palonosetron—Flatulence—Epirubicin—bone cancer	0.000294	0.00236	CcSEcCtD
Palonosetron—Dysgeusia—Epirubicin—bone cancer	0.000292	0.00234	CcSEcCtD
Palonosetron—Angiopathy—Doxorubicin—bone cancer	0.000287	0.00231	CcSEcCtD
Palonosetron—Immune system disorder—Doxorubicin—bone cancer	0.000286	0.0023	CcSEcCtD
Palonosetron—Mediastinal disorder—Doxorubicin—bone cancer	0.000286	0.00229	CcSEcCtD
Palonosetron—Chills—Doxorubicin—bone cancer	0.000284	0.00228	CcSEcCtD
Palonosetron—Arrhythmia—Doxorubicin—bone cancer	0.000283	0.00227	CcSEcCtD
Palonosetron—Nausea—Cisplatin—bone cancer	0.000281	0.00226	CcSEcCtD
Palonosetron—Alopecia—Doxorubicin—bone cancer	0.00028	0.00225	CcSEcCtD
Palonosetron—Mental disorder—Doxorubicin—bone cancer	0.000278	0.00223	CcSEcCtD
Palonosetron—Convulsion—Methotrexate—bone cancer	0.000276	0.00222	CcSEcCtD
Palonosetron—Malnutrition—Doxorubicin—bone cancer	0.000276	0.00221	CcSEcCtD
Palonosetron—Erythema—Doxorubicin—bone cancer	0.000276	0.00221	CcSEcCtD
Palonosetron—Anaemia—Epirubicin—bone cancer	0.000275	0.00221	CcSEcCtD
Palonosetron—Flatulence—Doxorubicin—bone cancer	0.000272	0.00218	CcSEcCtD
Palonosetron—Arthralgia—Methotrexate—bone cancer	0.000271	0.00218	CcSEcCtD
Palonosetron—Myalgia—Methotrexate—bone cancer	0.000271	0.00218	CcSEcCtD
Palonosetron—Dysgeusia—Doxorubicin—bone cancer	0.00027	0.00217	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000269	0.00216	CcSEcCtD
Palonosetron—Discomfort—Methotrexate—bone cancer	0.000268	0.00215	CcSEcCtD
Palonosetron—Anaphylactic shock—Methotrexate—bone cancer	0.00026	0.00209	CcSEcCtD
Palonosetron—Convulsion—Epirubicin—bone cancer	0.000258	0.00207	CcSEcCtD
Palonosetron—Infection—Methotrexate—bone cancer	0.000258	0.00207	CcSEcCtD
Palonosetron—Hypertension—Epirubicin—bone cancer	0.000257	0.00207	CcSEcCtD
Palonosetron—Nervous system disorder—Methotrexate—bone cancer	0.000255	0.00205	CcSEcCtD
Palonosetron—Anaemia—Doxorubicin—bone cancer	0.000255	0.00205	CcSEcCtD
Palonosetron—Arthralgia—Epirubicin—bone cancer	0.000254	0.00204	CcSEcCtD
Palonosetron—Myalgia—Epirubicin—bone cancer	0.000254	0.00204	CcSEcCtD
Palonosetron—Anxiety—Epirubicin—bone cancer	0.000253	0.00203	CcSEcCtD
Palonosetron—Skin disorder—Methotrexate—bone cancer	0.000252	0.00203	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000252	0.00202	CcSEcCtD
Palonosetron—Discomfort—Epirubicin—bone cancer	0.000251	0.00201	CcSEcCtD
Palonosetron—Dry mouth—Epirubicin—bone cancer	0.000248	0.00199	CcSEcCtD
Palonosetron—Anorexia—Methotrexate—bone cancer	0.000248	0.00199	CcSEcCtD
Palonosetron—Anaphylactic shock—Epirubicin—bone cancer	0.000243	0.00195	CcSEcCtD
Palonosetron—Hypotension—Methotrexate—bone cancer	0.000243	0.00195	CcSEcCtD
Palonosetron—Infection—Epirubicin—bone cancer	0.000242	0.00194	CcSEcCtD
Palonosetron—Shock—Epirubicin—bone cancer	0.000239	0.00192	CcSEcCtD
Palonosetron—Convulsion—Doxorubicin—bone cancer	0.000239	0.00192	CcSEcCtD
Palonosetron—Nervous system disorder—Epirubicin—bone cancer	0.000239	0.00192	CcSEcCtD
Palonosetron—Hypertension—Doxorubicin—bone cancer	0.000238	0.00191	CcSEcCtD
Palonosetron—Tachycardia—Epirubicin—bone cancer	0.000237	0.00191	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000237	0.0019	CcSEcCtD
Palonosetron—Skin disorder—Epirubicin—bone cancer	0.000236	0.0019	CcSEcCtD
Palonosetron—Insomnia—Methotrexate—bone cancer	0.000235	0.00189	CcSEcCtD
Palonosetron—Arthralgia—Doxorubicin—bone cancer	0.000235	0.00188	CcSEcCtD
Palonosetron—Myalgia—Doxorubicin—bone cancer	0.000235	0.00188	CcSEcCtD
Palonosetron—Anxiety—Doxorubicin—bone cancer	0.000234	0.00188	CcSEcCtD
Palonosetron—Paraesthesia—Methotrexate—bone cancer	0.000233	0.00187	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000233	0.00187	CcSEcCtD
Palonosetron—Discomfort—Doxorubicin—bone cancer	0.000232	0.00186	CcSEcCtD
Palonosetron—Anorexia—Epirubicin—bone cancer	0.000232	0.00186	CcSEcCtD
Palonosetron—Dyspnoea—Methotrexate—bone cancer	0.000232	0.00186	CcSEcCtD
Palonosetron—Somnolence—Methotrexate—bone cancer	0.000231	0.00186	CcSEcCtD
Palonosetron—Dry mouth—Doxorubicin—bone cancer	0.00023	0.00184	CcSEcCtD
Palonosetron—Dyspepsia—Methotrexate—bone cancer	0.000229	0.00184	CcSEcCtD
Palonosetron—Hypotension—Epirubicin—bone cancer	0.000227	0.00182	CcSEcCtD
Palonosetron—Decreased appetite—Methotrexate—bone cancer	0.000226	0.00181	CcSEcCtD
Palonosetron—Anaphylactic shock—Doxorubicin—bone cancer	0.000225	0.00181	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Methotrexate—bone cancer	0.000224	0.0018	CcSEcCtD
Palonosetron—Fatigue—Methotrexate—bone cancer	0.000224	0.0018	CcSEcCtD
Palonosetron—Infection—Doxorubicin—bone cancer	0.000224	0.0018	CcSEcCtD
Palonosetron—Pain—Methotrexate—bone cancer	0.000222	0.00178	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000222	0.00178	CcSEcCtD
Palonosetron—Shock—Doxorubicin—bone cancer	0.000221	0.00178	CcSEcCtD
Palonosetron—Nervous system disorder—Doxorubicin—bone cancer	0.000221	0.00177	CcSEcCtD
Palonosetron—Insomnia—Epirubicin—bone cancer	0.00022	0.00177	CcSEcCtD
Palonosetron—Tachycardia—Doxorubicin—bone cancer	0.00022	0.00176	CcSEcCtD
Palonosetron—Skin disorder—Doxorubicin—bone cancer	0.000219	0.00176	CcSEcCtD
Palonosetron—Paraesthesia—Epirubicin—bone cancer	0.000218	0.00175	CcSEcCtD
Palonosetron—Dyspnoea—Epirubicin—bone cancer	0.000217	0.00174	CcSEcCtD
Palonosetron—Somnolence—Epirubicin—bone cancer	0.000216	0.00174	CcSEcCtD
Palonosetron—Anorexia—Doxorubicin—bone cancer	0.000215	0.00172	CcSEcCtD
Palonosetron—Dyspepsia—Epirubicin—bone cancer	0.000214	0.00172	CcSEcCtD
Palonosetron—Gastrointestinal pain—Methotrexate—bone cancer	0.000213	0.00171	CcSEcCtD
Palonosetron—Decreased appetite—Epirubicin—bone cancer	0.000211	0.0017	CcSEcCtD
Palonosetron—Hypotension—Doxorubicin—bone cancer	0.00021	0.00169	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Epirubicin—bone cancer	0.00021	0.00169	CcSEcCtD
Palonosetron—Fatigue—Epirubicin—bone cancer	0.00021	0.00168	CcSEcCtD
Palonosetron—Pain—Epirubicin—bone cancer	0.000208	0.00167	CcSEcCtD
Palonosetron—Constipation—Epirubicin—bone cancer	0.000208	0.00167	CcSEcCtD
Palonosetron—Abdominal pain—Methotrexate—bone cancer	0.000205	0.00165	CcSEcCtD
Palonosetron—Body temperature increased—Methotrexate—bone cancer	0.000205	0.00165	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000205	0.00165	CcSEcCtD
Palonosetron—Insomnia—Doxorubicin—bone cancer	0.000204	0.00163	CcSEcCtD
Palonosetron—Paraesthesia—Doxorubicin—bone cancer	0.000202	0.00162	CcSEcCtD
Palonosetron—Dyspnoea—Doxorubicin—bone cancer	0.000201	0.00161	CcSEcCtD
Palonosetron—Somnolence—Doxorubicin—bone cancer	0.0002	0.00161	CcSEcCtD
Palonosetron—Gastrointestinal pain—Epirubicin—bone cancer	0.000199	0.0016	CcSEcCtD
Palonosetron—Dyspepsia—Doxorubicin—bone cancer	0.000198	0.00159	CcSEcCtD
Palonosetron—Decreased appetite—Doxorubicin—bone cancer	0.000196	0.00157	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000194	0.00156	CcSEcCtD
Palonosetron—Fatigue—Doxorubicin—bone cancer	0.000194	0.00156	CcSEcCtD
Palonosetron—Constipation—Doxorubicin—bone cancer	0.000192	0.00155	CcSEcCtD
Palonosetron—Pain—Doxorubicin—bone cancer	0.000192	0.00155	CcSEcCtD
Palonosetron—Body temperature increased—Epirubicin—bone cancer	0.000192	0.00154	CcSEcCtD
Palonosetron—Abdominal pain—Epirubicin—bone cancer	0.000192	0.00154	CcSEcCtD
Palonosetron—Hypersensitivity—Methotrexate—bone cancer	0.000192	0.00154	CcSEcCtD
Palonosetron—Asthenia—Methotrexate—bone cancer	0.000186	0.0015	CcSEcCtD
Palonosetron—Gastrointestinal pain—Doxorubicin—bone cancer	0.000184	0.00148	CcSEcCtD
Palonosetron—Pruritus—Methotrexate—bone cancer	0.000184	0.00148	CcSEcCtD
Palonosetron—Hypersensitivity—Epirubicin—bone cancer	0.000179	0.00144	CcSEcCtD
Palonosetron—Body temperature increased—Doxorubicin—bone cancer	0.000178	0.00143	CcSEcCtD
Palonosetron—Abdominal pain—Doxorubicin—bone cancer	0.000178	0.00143	CcSEcCtD
Palonosetron—Diarrhoea—Methotrexate—bone cancer	0.000178	0.00143	CcSEcCtD
Palonosetron—Asthenia—Epirubicin—bone cancer	0.000175	0.0014	CcSEcCtD
Palonosetron—Pruritus—Epirubicin—bone cancer	0.000172	0.00138	CcSEcCtD
Palonosetron—Dizziness—Methotrexate—bone cancer	0.000172	0.00138	CcSEcCtD
Palonosetron—Diarrhoea—Epirubicin—bone cancer	0.000166	0.00134	CcSEcCtD
Palonosetron—Hypersensitivity—Doxorubicin—bone cancer	0.000166	0.00133	CcSEcCtD
Palonosetron—Vomiting—Methotrexate—bone cancer	0.000165	0.00133	CcSEcCtD
Palonosetron—Rash—Methotrexate—bone cancer	0.000164	0.00132	CcSEcCtD
Palonosetron—Dermatitis—Methotrexate—bone cancer	0.000164	0.00131	CcSEcCtD
Palonosetron—Headache—Methotrexate—bone cancer	0.000163	0.00131	CcSEcCtD
Palonosetron—Asthenia—Doxorubicin—bone cancer	0.000161	0.0013	CcSEcCtD
Palonosetron—Dizziness—Epirubicin—bone cancer	0.000161	0.00129	CcSEcCtD
Palonosetron—Pruritus—Doxorubicin—bone cancer	0.000159	0.00128	CcSEcCtD
Palonosetron—Vomiting—Epirubicin—bone cancer	0.000155	0.00124	CcSEcCtD
Palonosetron—Nausea—Methotrexate—bone cancer	0.000154	0.00124	CcSEcCtD
Palonosetron—Diarrhoea—Doxorubicin—bone cancer	0.000154	0.00124	CcSEcCtD
Palonosetron—Rash—Epirubicin—bone cancer	0.000153	0.00123	CcSEcCtD
Palonosetron—Dermatitis—Epirubicin—bone cancer	0.000153	0.00123	CcSEcCtD
Palonosetron—Headache—Epirubicin—bone cancer	0.000152	0.00122	CcSEcCtD
Palonosetron—Dizziness—Doxorubicin—bone cancer	0.000149	0.00119	CcSEcCtD
Palonosetron—Nausea—Epirubicin—bone cancer	0.000144	0.00116	CcSEcCtD
Palonosetron—Vomiting—Doxorubicin—bone cancer	0.000143	0.00115	CcSEcCtD
Palonosetron—Rash—Doxorubicin—bone cancer	0.000142	0.00114	CcSEcCtD
Palonosetron—Dermatitis—Doxorubicin—bone cancer	0.000142	0.00114	CcSEcCtD
Palonosetron—Headache—Doxorubicin—bone cancer	0.000141	0.00113	CcSEcCtD
Palonosetron—Nausea—Doxorubicin—bone cancer	0.000134	0.00107	CcSEcCtD
